[First results of parenteral treatment of male fertility disorders using kallikrein: oligozoospermia].
57 andrological patients with oligozoospermia were treated with kallikrein--a kinin-liberating proteinase--over a period of 7 weeks. The statistical analysis of the different semen parameters showed that during parenteral application of 3 X 40 KU Kallikrein per week a significant increase of the sperm motility (total motility and progressive motility) occurred. Improvement of sperm motility did exist during the observation period up to 3 months after withdrawl of the therapy. 2, 3 and 5 months after beginning of the treatment a significant increase of the sperm count was found. A significant increase of the total sperm output was observed 3 and 5 months after initiation of the medication. Finally, the percentage of normal shaped spermatozoa was increased 2 and 5 months after beginning the kallikrein application. The conception rate was 28%.
D005260:Female; D006801:Humans; D007610:Kallikreins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D013081:Sperm Motility / Q000187:drug effects; D013091:Spermatogenesis / Q000187:drug effects
D007610:Kallikreins
Erste Ergebnisse einer parenteralen Behandlung von männlichen Fertilitätsstörungen mit Kallikrein: Oligozoospermie